Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2023-09-29
Target enrollment:
Participant gender:
Summary
Multicentre, prospective, observational, open-label, single arm, post-marketing study
intended to record Lenalidomide/Dexamethasone treatment data from patients with
relapsed/refractory Multiple Myeloma (rrMM) treated under the settings defined by the
standard clinical practice and approved Summary of Product Characteristics (SmPC).